Influence of long-term physical activity on serum PCSK9, HDL/LDL-cholesterol and lipoprotein a-levels

被引：0
|
作者：
Sponder, M. [1 ]
Campean, I. A. [1 ]
Dalos, D. [1 ]
Emich, M. [2 ]
Fritzer-Szekeres, M. [3 ]
Litschauer, B. [4 ]
Bergler-Klein, J. [1 ]
Graf, S. [1 ]
Strametz-Juranek, J. [1 ]
机构：
[1] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Vienna, Austria
[2] Med Univ Vienna, Fed Minist Def & Sports, Vienna, Austria
[3] Univ Vienna, Dept Med & Chem Lab Diagnost, Vienna, Austria
[4] Med Univ Vienna, Clin Pharmacol, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1516
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [31] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Davignon, Jean
    Dubuc, Genevieve
    Seidah, Nabil G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) : 308 - 315
  • [32] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Jean Davignon
    Geneviève Dubuc
    Nabil G. Seidah
    Current Atherosclerosis Reports, 2010, 12 : 308 - 315
  • [33] PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
    Marais, A. David
    Kim, Jae B.
    Wasserman, Scott M.
    Lambert, Gilles
    PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 58 - 66
  • [34] Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
    Schmidt, Amand F.
    Holmes, Michael V.
    Preiss, David
    Swerdlow, Daniel I.
    Denaxas, Spiros
    Fatemifar, Ghazaleh
    Faraway, Rupert
    Finan, Chris
    Valentine, Dennis
    Fairhurst-Hunter, Zammy
    Hartwig, Fernando Pires
    Horta, Bernardo Lessa
    Hypponen, Elina
    Power, Christine
    Moldovan, Max
    van Iperen, Erik
    Hovingh, Kees
    Demuth, Ilja
    Norman, Kristina
    Steinhagen-Thiessen, Elisabeth
    Demuth, Juri
    Bertram, Lars
    Lill, Christina M.
    Coassin, Stefan
    Willeit, Johann
    Kiechl, Stefan
    Willeit, Karin
    Mason, Dan
    Wright, John
    Morris, Richard
    Wanamethee, Goya
    Whincup, Peter
    Ben-Shlomo, Yoav
    McLachlan, Stela
    Price, Jackie F.
    Kivimaki, Mika
    Welch, Catherine
    Sanchez-Galvez, Adelaida
    Marques-Vidal, Pedro
    Nicolaides, Andrew
    Panayiotou, Andrie G.
    Onland-Moret, N. Charlotte
    van der Schouw, Yvonne T.
    Matullo, Giuseppe
    Fiorito, Giovanni
    Guarrera, Simonetta
    Sacerdote, Carlotta
    Wareham, Nicholas J.
    Langenberg, Claudia
    Scott, Robert A.
    BMC CARDIOVASCULAR DISORDERS, 2019, 19 (01)
  • [35] LDL-CHOLESTEROL REDUCTION WITH PCSK9 INHIBITORS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
    Casula, Manuela
    Scotti, Lorenza
    Bernocchi, Ottavia
    Galimberti, Federica
    Tragni, Elena
    Corrao, Giovanni
    Catapano, Alberico Luigi
    ATHEROSCLEROSIS, 2017, 263 : E244 - E244
  • [36] Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
    Amand F. Schmidt
    Michael V. Holmes
    David Preiss
    Daniel I. Swerdlow
    Spiros Denaxas
    Ghazaleh Fatemifar
    Rupert Faraway
    Chris Finan
    Dennis Valentine
    Zammy Fairhurst-Hunter
    Fernando Pires Hartwig
    Bernardo Lessa Horta
    Elina Hypponen
    Christine Power
    Max Moldovan
    Erik van Iperen
    Kees Hovingh
    Ilja Demuth
    Kristina Norman
    Elisabeth Steinhagen-Thiessen
    Juri Demuth
    Lars Bertram
    Christina M. Lill
    Stefan Coassin
    Johann Willeit
    Stefan Kiechl
    Karin Willeit
    Dan Mason
    John Wright
    Richard Morris
    Goya Wanamethee
    Peter Whincup
    Yoav Ben-Shlomo
    Stela McLachlan
    Jackie F. Price
    Mika Kivimaki
    Catherine Welch
    Adelaida Sanchez-Galvez
    Pedro Marques-Vidal
    Andrew Nicolaides
    Andrie G. Panayiotou
    N. Charlotte Onland-Moret
    Yvonne T. van der Schouw
    Giuseppe Matullo
    Giovanni Fiorito
    Simonetta Guarrera
    Carlotta Sacerdote
    Nicholas J. Wareham
    Claudia Langenberg
    Robert A. Scott
    BMC Cardiovascular Disorders, 19
  • [37] New homogeneous assays for estimation of serum HDL and LDL-cholesterol levels.
    Kakuyama, T
    Ochiai, K
    Kishi, K
    Ohta, Y
    Uemura, Y
    Kayamori, Y
    Katayama, Y
    Nakamura, M
    CLINICAL CHEMISTRY, 2001, 47 (06) : A55 - A56
  • [38] Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
    Steinberg, Daniel
    Witztum, Joseph L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) : 9546 - 9547
  • [39] Baseline levels of LDL-cholesterol and lipoprotein(A) and the Ava II polymorphism of the LDL receptor gene influence the response of LDL-cholesterol to pravastatin treatment
    Lahoz, M
    Pena, R
    Mostaza, JM
    Laguna, F
    Garcia-Iglesias, MF
    Taboada, K
    Pinto, X
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 21 - 21
  • [40] INFLUENCE OF PHYSIOLOGICAL CHANGES IN ENDOGENOUS ESTROGEN ON CIRCULATING PCSK9 AND LDL CHOLESTEROL
    Ghosh, M.
    Galman, C.
    Rudling, M. A. T. S.
    Angelin, B. O.
    ATHEROSCLEROSIS, 2015, 241 (01) : E16 - E16
12345